Spyre Therapeutics, Inc. — Director's Dealing 2021

Jun 22, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2021-06-18

Reporting Person: Souza Marcio (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-18	Director Stock Option (right to buy)	$6.44	A	60000	Acquired	2031-06-17	Common Stock (60000)	Direct

Footnotes

F1: The stock option vests and becomes exercisable in 36 equal monthly installments beginning on July 18, 2021 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.